Benzothiophene antibiotic potentiators and inhibitors of osteomyelitis

Benzothiophene compounds targeting PBP4 in MRSA restore antibiotic sensitivity and prevent osteomyelitis by inhibiting PBP4, addressing antibiotic resistance and chronic infections in Staphylococcus aureus.

WO2026236686A1PCT designated stage Publication Date: 2026-11-12UNIV OF NOTRE DAME DU LAC +5
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027405
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-08
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Antibiotic resistance in Staphylococcus aureus, particularly methicillin-resistant strains (MRSA), leads to chronic osteomyelitis infections due to the bacterial colonization of cortical bone osteocyte lacuna-canalicular networks, necessitating new treatment approaches that target Penicillin Binding Protein 4 (PBP4) to overcome resistance and prevent infection.

Method used

Development of benzothiophene compounds that inhibit PBP4, acting as adjuvants to restore antibiotic sensitivity and prevent osteomyelitis by targeting PBP2a and PBP4, thereby resensitizing MRSA to antibiotics like oxacillin.

Benefits of technology

The benzothiophene compounds effectively lower the minimum inhibitory concentration of oxacillin in MRSA strains, providing a dual function of inhibiting PBP4 and preventing osteomyelitis, offering a potential treatment for chronic infections.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026027405_12112026_PF_FP_ABST
    Figure US2026027405_12112026_PF_FP_ABST
Patent Text Reader

Abstract

Penicillin binding protein 4 (PBP4) is a key determinant for resistance in methicillin-resistant Staphylococcus aureus (MRSA). PBP4 is essential for Staphylococcus aureus to infect the cortical bone osteocyte lacuna-canalicular network, which causes osteomyelitis and creates a bacterial niche for recurring bone infection. We uncovered a compound through a structure activity relationship study that lowers the minimum inhibitory concentration of oxacillin 32-fold at 5 µM in oxacillin-resistant MRSA ATCC 1556. We show that PBP4 inhibitors can function as therapeutics to prevent osteomyelitis while also reversing PBP4-mediated β-lactam resistance. Herein we report compounds that act as PBP2a and PBP4 inhibitors. These compounds can be paired with beta lactam antibiotics to restore beta lactam sensitivity and can be used prophylactically to prevent infections such as osteomyelitis.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] BENZOTHIOPHENE ANTIBIOTIC POTENTIATORS AND INHIBITORS OF OSTEOMYELITIS

[0002] RELATED APPLICATIONS

[0003] This application claims priority under 35 U. S. C. §119(e) to U. S. Provisional Patent Application No. 63 / 802,347, filed May 8, 2025, which is incorporated herein by reference.

[0004] GOVERNMENT SUPPORT

[0005] This invention was made with government support under AR072000 awarded by the National Institutes of Health. The government has certain rights in the invention.

[0006] BACKGROUND OF THE INVENTION

[0007] Antibiotic resistance is a well-established global health threat. Staphylococcus aureus is one of the six ESKAPE pathogens (Enterococcus faecium, S. aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and the Enterobacter species), a group of pathogens notorious for their multidrug resistance (MDR). Although the introduction of new antibiotics has historically been employed to combat MDR threats, the rapid development of antibiotic resistance coupled with large pharmaceutical companies exit from antibiotic development has prompted investigation into orthogonal approaches to address these resistant bacteria. One solution is through use of adjuvants, which are compounds that do not possess antimicrobial properties, but aid existing antibiotics by interrupting bacterial resistance mechanisms that render antibiotics inactive. A common example of an antibiotic adjuvant is the P-lactamase inhibitor clavulanic acid, which is paired with the P-lactam antibiotic amoxicillin. Currently, the only clinically approved adjuvants target P-lactamases; however, additional defense mechanisms that can be targeted in bacteria to overcome resistance.

[0008] Staphylococcus aureus is the main cause of osteomyelitis, a disease characterized by infection and inflammation of the bone. Osteomyelitis largely impacts individuals who are immobile or disabled, suffering with diabetes, and those who have experienced trauma that leads to exposed skin or reconstructive surgery. Treatment options for osteomyelitis are limited, intense, and typically resort to amputation. Osteomyelitis is characterized by the bacterial invasion of the cortical bone osteocyte lacuna-canalicular network (OLCN), which leads to chronic infection, and is characterized by frequent relapses in infection.

[0009] Penicillin binding proteins (PBPs) are transpeptidases that are responsible for crosslinking peptidoglycan to build the bacterial cell wall. Penicillin binding protein 4 (PBP4) is a low molecular weight PBP with transpeptidase activity. Multiple classes of PBPs are involved inresistance to P-lactams, however PBP4 has been observed to mediate resistance to ceftobiprole (BPR) and ceftaroline, both fifth generation P-lactams developed to treat methicillin-resistant Staphylococcus aureus (MRSA) infections. Under most conditions, PBP4 is non-essential.

[0010] In *S. aureus*, the pbp4 gene encodes for the PBP4 enzyme, in turn mediating P-lactam resistance. Previously, a strain of MRSA with a pbp4 deletion was unable to colonize OLCNs. In vitro screenings using Microfluidic-Silicon Membrane-Canalicular Arrays (pSiM-CA), which are devices with 500 nm pores that mimic the opening of canaliculi, determined that MRSA strains with a pbp4 deletion were unable to cross artificial pores, suggesting that PBP4 is essential for S. aureus to colonize OLCNs.

[0011] A suitable solution and treatment option for the prevention of osteomyelitis would be to employ small molecules that target PBP4 and prevent bacteria from invading OLCNs. Molecules that target PBP4 could have dual roles: overcome resistance mechanisms and fight MRSA infection that leads to osteomyelitis.

[0012] SUMMARY

[0013] This disclosure provides a series of benzothiophene compounds that target PBP2a and / or PBP4. Compounds that bind PBP2a serve as adjuvants for / icw-laclain antibiotics and resensitize MRSA to antibiotics such as oxacillin. Compounds that target PBP4 have dual function: restoration of sensitivity to fifth generation cephalosporins and inhibition of osteomyelitis.

[0014] Accordingly, this disclosure provides a compound of Formula I:

[0015] Heteroaryl-Amido (I),

[0016] wherein.

[0017] Heteroaryl is represented by Formula LAI, IA2, IA3, or 1A4:

[0018]

[0019] wherein,

[0020] each J1is S, 0, or NRawherein Rais H or -(Ci-Ce)alkyl;

[0021] each J2is CRbwherein Rbis H or -(Ci-Ce)alkyl, or each J2is N;

[0022] each R1is H, halo, or — (Ci-Ce)alkyl;

[0023] each Rlbis H, halo, or -(Ci-Ce)alkyl; and

[0024] each R2is H, halo, or -(Ci-Ce)alkyl;

[0025] Amido is represented by Formula IB1:

[0026]

[0027] Amin (IB1),

[0028] wherein,

[0029] Amin is heterocycloalkyl or N(RC)2 wherein each Rcis independently -(Ci-C6)alkyl;

[0030] L is absent or NRCwherein Rcis H or -(Ci-Ce)alkyl;

[0031] R3is H or -(Ci-Ce)alkyl;

[0032] R4is H, halo, or unsubstituted or substituted -(Ci-Ce)alkyl; and

[0033] R5is H, -(Ci-Ce)alkyl, or halo provided that halo is not ortho to the amide moiety of Formula 1B1;

[0034] or a salt thereof.

[0035] This disclosure also provides a method for treating a methicillin-resistant Staphylococcus aureus (MRSA) infection comprising administering a combination of an antibiotic and an adjuvant comprising a compound described herein to a subject in need thereof, wherein the MRSA infection is thereby treated.

[0036] The invention provides novel compounds of Formula I, intermediates for the synthesis of compounds of Formula I, as well as methods of preparing compounds of Formula I. The invention also provides compounds of Formula I that are useful as intermediates for the synthesis of other useful compounds. The invention provides for the use of compounds of Formula I for the manufacture of medicaments useful for the treatment of bacterial infections in a mammal, such as a human.

[0037] The invention provides for the use of the compositions described herein for use in medical therapy. The medical therapy can be treating a bacterial infection, including but not limited to a MRSA infection. The invention also provides for the use of a composition as described herein for the manufacture of a medicament to treat an infection in a mammal, for example, a MRSA in a human. The medicament can include a pharmaceutically acceptable diluent, excipient, or carrier.

[0038] BRIEF DESCRIPTION OF THE DRAWINGS

[0039] The following drawings form part of the specification and are included to further demonstrate certain embodiments or various aspects of the invention. In some instances, embodiments of the invention can be best understood by referring to the accompanying drawings in combination with the detailed description presented herein. The description and accompanying drawings may highlight a certain specific example, or a certain aspect of theinvention. However, one skilled in the art will understand that portions of the example or aspect may be used in combination with other examples or aspects of the invention.

[0040] Figure 1. MRSA 43300 growth curves for NDM-335 and oxacillin. Data ± SD from at least three replicates.

[0041] Figure 2. MRSA 43300 growth curves for NDM-427 and oxacillin. Data + SD from at least three replicates.

[0042] Figure 3. MRSA 43300 growth curves for NDM-400 and oxacillin. Data ± SD from at least three replicates.

[0043] Figure 4A-C. qRT-PCR studies with varying concentrations of NDM-335 against (A) mecA, (B) graR, and (C) graS.

[0044] DETAILED DESCRIPTION

[0045] Exploration of a Benzothiophene Scaffold for Use as Adjuvants for ff Lactam Antibiotics against Methicillin Resistant Staphylococcus aureus.

[0046] Antibiotic resistance and the diminishing interest in antibiotic development creates a precedent for a future without treatments for bacterial infections. Penicillin binding protein 4 (PBP4) is a key determinant for resistance in methicillin-resistant Staphylococcus aureus (MRSA). PBP4 is essential for Staphylococcus aureus to infect the cortical bone osteocyte lacuna-canalicular network (OLCN), which causes osteomyelitis and creates a bacterial niche for recurring bone infection. Previously reported library screens identified compound 1, a benzothiophene-containing compound, with putative PBP4 inhibitory activity. We uncovered a compound through a structure activity relationship (SAR) study that lowers the minimum inhibitory concentration (MIC) of oxacillin 32-fold at 5 pM in oxacillin-resistant MRSA ATCC 1556. We show that the further development of a PBP4 inhibitor can function as both a therapeutic to prevent osteomyelitis and reverse PBP4-mediated -lactam resistance.

[0047] Herein we report the optimization of parent compound 1, which revealed several compounds that act as putative PBP2a and PBP4 inhibitors. These compounds can be paired with beta lactam antibiotics to restore beta lactam sensitivity or be used prophylactically to prevent Osteomyelitis.

[0048] Chart 1. Structure of compound 1 depicting benzothiophene head, phenyl core, and piperazine tail as ideal regions of structure activity relationship (SAR) exploration.

[0049]

[0050] Compound 1Definitions.

[0051] The following definitions are included to provide a clear and consistent understanding of the specification and claims. As used herein, the recited terms have the following meanings. All other terms and phrases used in this specification have their ordinary' meanings as one of skill in the art would understand. Such ordinary meanings may be obtained by reference to technical dictionaries, such as Hawley’s Condensed Chemical Dictionary 14thEdirion, by R. J. Lewis, John Wiley & Sons, New York, N. Y., 2001.

[0052] References in the specification to "one embodiment", "an embodiment", etc., indicate that the embodiment described may include a particular aspect, feature, structure, moiety, or characteristic, but not every embodiment necessarily includes that aspect, feature, structure, moiety, or characteristic. Moreover, such phrases may, but do not necessarily, refer to the same embodiment referred to in other portions of the specification. Further, when a particular aspect, feature, structure, moiety, or characteristic is described in connection with an embodiment, it is within the knowledge of one skilled in the art to affect or connect such aspect, feature, structure, moiety, or characteristic with other embodiments, whether or not explicitly described.

[0053] The singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a compound" includes a plurality of such compounds, so that a compound X includes a plurality of compounds X. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for the use of exclusive terminology, such as "solely," "only," and the like, in connection with any element described herein, and / or the recitation of claim elements or use of "negative" limitations.

[0054] The term "and / or" means any one of the items, any combination of the items, or all of the items with which this term is associated. The phrases "one or more" and "at least one" are readily understood by one of skill in the art, particularly when read in context of its usage. For example, the phrase can mean one, two, three, four, five, six, ten, 100, or any upper limit approximately 10, 100, or 1000 times higher than a recited lower limit. For example, one or more substituents on a phenyl ring refers to one to five, or one to four, for example if the phenyl ring is disubstituted.

[0055] As will be understood by the skilled artisan, all numbers, including those expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and so forth, are approximations and are understood as being optionally modified in all instances by the term "about." These values can vary depending upon the desired properties sought to be obtained by those skilled in the art utilizing the teachings of the descriptions herein. It is also understood that such values inherently contain variability resulting from the standard deviations found in theirrespective testing measurements. When values are expressed as approximations, by use of the antecedent "about," it will be understood that the particular value without the modifier "about" also forms a further aspect.

[0056] The terms "about" and "approximately" are used interchangeably. Both terms can refer to a variation of ± 5%, + 10%, ± 20%, or ± 25% of the value specified. For example, "about 50" percent can in some embodiments carry a variation from 45 to 55 percent, or as otherwise defined by a particular claim. For integer ranges, the term "about" can include one or two integers greater than and / or less than a recited integer at each end of the range. Unless indicated otherwise herein, the terms "about" and "approximately" are intended to include values, e.g., weight percentages, proximate to the recited range that are equivalent in terms of the functionality of the individual ingredient, composition, or embodiment. The terms "about" and "approximately" can also modify the endpoints of a recited range as discussed above in this paragraph.

[0057] As will be understood by one skilled in the art, for any and all purposes, particularly in terms of providing a written description, all ranges recited herein also encompass any and all possible sub-ranges and combinations of sub-ranges thereof, as well as the individual values making up the range, particularly integer values. It is therefore understood that each unit between two particular units are also disclosed. For example, if 10 to 15 is disclosed, then 11, 12, 13, and 14 are also disclosed, individually, and as part of a range. A recited range (e.g., weight percentages or carbon groups) includes each specific value, integer, decimal, or identity within the range. Any listed range can be easily recognized as sufficiently describing and enabling the same range being broken down into at least equal halves, thirds, quarters, fifths, or tenths. As a non-limiting example, each range discussed herein can be readily broken down into a lower third, middle third and upper third, etc. As will also be understood by one skilled in the art, all language such as "up to", "at least", "greater than", "less than", "more than", "or more", and the like, include the number recited and such terms refer to ranges that can be subsequently broken down into sub-ranges as discussed above. In the same manner, all ratios recited herein also include all sub-ratios falling within the broader ratio. Accordingly, specific values recited for radicals, substituents, and ranges, are for illustration only; they do not exclude other defined values or other values within defined ranges for radicals and substituents. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint.

[0058] This disclosure provides ranges, limits, and deviations to variables such as volume, mass, percentages, ratios, etc. It is understood by an ordinary person skilled in the art that a range, such as “number 1” to “number2”, implies a continuous range of numbers that includes the wholenumbers and fractional numbers. For example, 1 to 10 means 1, 2, 3, 4, 5,... 9, 10. It also means 1.0, 1.1, 1.2. 1.3,..., 9.8, 9.9, 10.0, and also means 1.01, 1.02, 1.03, and so on. If the variable disclosed is a number less than “number10”, it implies a continuous range that includes whole numbers and fractional numbers less than number10, as discussed above. Similarly, if the variable disclosed is a number greater than “number10”, it implies a continuous range that includes whole numbers and fractional numbers greater than number10. These ranges can be modified by the term “about”, whose meaning has been described above.

[0059] The recitation of a), b), c),...or i), ii), iii), or the like in a list of components or steps do not confer any particular order unless explicitly stated.

[0060] One skilled in the art will also readily recognize that where members are grouped together in a common manner, such as in a Markush group, the invention encompasses not only the entire group listed as a whole, but each member of the group individually and all possible subgroups of the main group. Additionally, for all purposes, the invention encompasses not only the main group, but also the main group absent one or more of the group members. The invention therefore envisages the explicit exclusion of any one or more of members of a recited group. Accordingly, provisos may apply to any of the disclosed categories or embodiments whereby any one or more of the recited elements, species, or embodiments, may be excluded from such categories or embodiments, for example, for use in an explicit negative limitation.

[0061] The term "contacting" refers to the act of touching, making contact, or of bringing to immediate or close proximity, including at the cellular or molecular level, for example, to bring about a physiological reaction, a chemical reaction, or a physical change, e.g., in a solution, in a reaction mixture, in vitro, or in vivo.

[0062] An "effective amount" refers to an amount effective to treat a disease, disorder, and / or condition, or to bring about a recited effect. For example, an effective amount can be an amount effective to reduce the progression or severity of the condition or symptoms being treated.

[0063] Determination of a therapeutically effective amount is well within the capacity of persons skilled in the art. The term "effective amount" is intended to include an amount of a compound described herein, or an amount of a combination of compounds described herein, e.g., that is effective to treat or prevent a disease or disorder, or to treat the symptoms of the disease or disorder, in a host. Thus, an "effective amount" generally means an amount that provides the desired effect.

[0064] Alternatively, the terms "effective amount" or "therapeutically effective amount," as used herein, refer to a sufficient amount of an agent or a composition or combination of compositions being administered which will relieve to some extent one or more of the symptoms of the disease or condition being treated. The result can be reduction and / or alleviation of the signs, symptoms,or causes of a disease, or any other desired alteration of a biological system. For example, an "effective amount" for therapeutic uses is the amount of the composition comprising a compound as disclosed herein required to provide a clinically significant decrease in disease symptoms. An appropriate "effective" amount in any individual case may be determined using techniques, such as a dose escalation study. The dose could be administered in one or more administrations. However, the precise determination of what would be considered an effective dose may be based on factors individual to each patient, including, but not limited to, the patient's age, size, type or extent of disease, stage of the disease, route of administration of the compositions, the type or extent of supplemental therapy used, ongoing disease process and type of treatment desired (e.g., aggressive vs. conventional treatment).

[0065] The terms "treating", "treat" and "treatment" include (i) preventing a disease, pathologic or medical condition from occurring (e.g., prophylaxis); (ii) inhibiting the disease, pathologic or medical condition or arresting its development: (iii) relieving the disease, pathologic or medical condition; and / or (iv) diminishing symptoms associated with the disease, pathologic or medical condition. Thus, the terms "treat", "treatment", and "treating" can extend to prophylaxis and can include prevent, prevention, preventing, lowering, stopping or reversing the progression or severity of the condition or symptoms being treated. As such, the term "treatment" can include medical, therapeutic, and / or prophylactic administration, as appropriate.

[0066] As used herein, "subject" or “patient” means an individual having symptoms of, or at risk for, a disease or other malignancy. A patient may be human or non-human and may include, for example, animal strains or species used as “model systems” for research purposes, such a mouse model as described herein. Likewise, the patient may include either adults or juveniles (e.g., children). Moreover, patient may mean any living organism, preferably a mammal (e.g., human or non-human) that may benefit from the administration of compositions contemplated herein. Examples of mammals include, but are not limited to, any member of the Mammalian class: humans, non-human primates such as chimpanzees, and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice and guinea pigs, and the like. Examples of non-mammals include, but are not limited to, birds, fish and the like. In one embodiment of the methods provided herein, the mammal is a human.

[0067] As used herein, the terms “providing”, “administering,” “introducing,” are used interchangeably herein and refer to the placement of a compound of the disclosure into a subject by a method or route that results in at least partial localization of the compound to a desired site. The compound can be administered by any appropriate route that results in delivery to a desired location in the subject.The compound and compositions described herein may be administered with additional compositions to prolong stability and activity of the compositions, or in combination with other therapeutic drugs.

[0068] The terms "inhibit", "inhibiting", and "inhibition" refer to the slowing, halting, or reversing the growth or progression of a disease, infection, condition, or group of cells. The inhibition can be greater than about 20%, 40%, 60%, 80%, 90%, 95%, or 99%, for example, compared to the growth or progression that occurs in the absence of the treatment or contacting.

[0069] The term “substantially” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, being largely but not necessarily wholly that which is specified. For example, the term could refer to a numerical value that may not be 100% the full numerical value. The full numerical value may be less by about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, or about 20%.

[0070] Wherever the term “comprising” is used herein, options are contemplated wherein the terms “consisting of’ or “consisting essentially of’ are used instead. As used herein, “comprising” is synonymous with "including," "containing," or "characterized by," and is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. As used herein, "consisting of" excludes any element, step, or ingredient not specified in the aspect element. As used herein, "consisting essentially of" does not exclude materials or steps that do not materially affect the basic and novel characteristics of the aspect. In each instance herein any of the terms "comprising", "consisting essentially of" and "consisting of" may be replaced with either of the other two terms. The disclosure illustratively described herein may be suitably practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein.

[0071] This disclosure provides methods of making the compounds and compositions of the invention. The compounds and compositions can be prepared by any of the applicable techniques described herein, optionally in combination with standard techniques of organic synthesis. Many techniques such as etherification and esterification are well known in the art. However, many of these techniques are elaborated in Compendium of Organic Synthetic Methods (John Wiley & Sons, New York), Vol. 1, Ian T. Harrison and Shuyen Harrison, 1971; Vol. 2, Ian T. Harrison and Shuyen Harrison, 1974; Vol. 3, Louis S. Hegedus and Leroy Wade, 1977; Vol. 4, Leroy G. Wade, Jr., 1980; Vol. 5, Leroy G. Wade, Jr., 1984; and Vol. 6; as well as standard organic reference texts such as March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5th Ed., by M. B. Smith and J. March (John Wiley & Sons, New York, 2001);

[0072] Comprehensive Organic Synthesis. Selectivity, Strategy & Efficiency in Modern Organic Chemistry. In 9 Volumes, Barry M. Trost, Editor-in-Chief (Pergamon Press, New York, 1993printing); Advanced Organic Chemistry, Part B: Reactions and Synthesis, Second Edition, Cary and Sundberg (1983); for heterocyclic synthesis see Hermanson, Greg T,, Bioconjugate Techniques, Third Edition, Academic Press, 2013.

[0073] The formulas and compounds described herein can be modified using protecting groups. Suitable amino and carboxy protecting groups are known to those skilled in the art (see for example, Protecting Groups in Organic Synthesis, Second Edition, Greene, T. W., and Wuts, P. G. M., John Wiley & Sons, New York, and references cited therein; Philip J. Kocienski;

[0074] Protecting Groups (Georg Thieme Verlag Stuttgart, New York, 1994), and references cited therein); and Comprehensive Organic Transformations, Larock, R. C., Second Edition, John Wiley & Sons, New York (1999), and referenced cited therein.

[0075] The term "halo" or "halide" refers to fluoro, chloro, bromo, or iodo. Similarly, the term "halogen" refers to fluorine, chlorine, bromine, and iodine.

[0076] The term "alkyl" refers to a branched or unbranched hydrocarbon having, for example, from 1-20 carbon atoms, and often 1-12, 1-10, 1-8, 1-6, or 1-4 carbon atoms; or for example, a range between 1-20 carbon atoms, such as 2-6, 3-6, 2-8, or 3-8 carbon atoms. As used herein, the term “alkyl” also encompasses a “cycloalkyl”, defined below. Examples include, but are not limited to, methyl, ethyl, 1-propyl, 2-propyl (Ao-propyl), 1-butyl, 2-methyl-l -propyl (isobutyl), 2 -butyl (sec-butyl), 2-methyl-2-propyl (t-butyl), 1 -pentyl, 2 -pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl- 1-butyl, 2-methyl-l -butyl, 1 -hexyl, 2 -hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3 -methyl- 3 -pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl, 3,3-dimethyl-2-butyl, hexyl, octyl, decyl, dodecyl, and the like. The alkyl can be unsubstituted or substituted, for example, with a substituent described below or otherwise described herein. JTie alkyl can also be optionally partially or fully unsaturated. As such, the recitation of an alkyl group can include an alkenyl group or an alkynyl group. The alkyl can be a monovalent hydrocarbon radical, as described and exemplified above, or it can be a divalent hydrocarbon radical (i.e., an alkylene).

[0077] An alkylene is an alkyl group having two free valences at a carbon atom or two different carbon atoms of a carbon chain. Similarly, alkenylene and alkynylene are respectively an alkene and an alkyne having two free valences at two different carbon atoms, or an alkenylene can have the two free valences on the same carbon.

[0078] The term "cycloalkyl" refers to cyclic alkyl groups of, for example, from 3 to 10 carbon atoms having a single cyclic ring or multiple condensed rings. Cycloalkyl groups include, by way of example, single ring structures such as cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyl, and the like, or multiple ring structures such as adamantyl, and the like. The cycloalkyl can be unsubstituted or substituted. The cycloalkyl group can be monovalent or divalent and can beoptionally substituted as described for alkyl groups. The cycloalkyl group can optionally include one or more cites of unsaturation, for example, the cycloalkyl group can include one or more carbon-carbon double bonds, such as, for example, 1 -cyclopent- 1-enyl, l-cyclopent-2-enyl, 1-cyclopent-3-enyl, cyclohexyl, 1 -cyclohex- 1-enyl, l-cyclohex-2-enyl, l-cyclohex-3-enyl, and the like.

[0079] The term “heteroatom” refers to any atom in the periodic table that is not carbon or hydrogen. Typically, a heteroatom is 0, S, N, P. The heteroatom may also be a halogen, metal or metalloid.

[0080] The term "heterocycloalkyl" or “heterocyclyl” refers to a saturated or partially saturated monocyclic, bicyclic, or polycyclic ring containing at least one heteroatom selected from nitrogen, sulfur, oxygen, preferably from 1 to 3 heteroatoms in at least one ring. Each ring is preferably from 3- to 10-membered, more preferably 4 to 7 membered. Examples of suitable heterocycloalkyl substituents include pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiofuranyl, piperidinyl, piperazinyl, tetrahydropyranyl, morpholinyl, 1,3-diazapanyl, 1,4-diazapanyl, 1,4-oxazepanyl, and 1,4-oxathiapanyl. The group may be a terminal group or a bridging group.

[0081] The term "aryl" refers to an aromatic hydrocarbon group derived from the removal of at least one hydrogen atom from a single carbon atom of a parent aromatic ring system. The radical attachment site can be at a saturated or unsaturated carbon atom of the parent ring system. The aryl group can have from 6 to 30 carbon atoms, for example, about 6-10 carbon atoms. The aryl group can have a single ring (e.g., phenyl) or multiple condensed (fused) rings, wherein at least one ring is aromatic (e.g., naphthyl, dihydrophenanthrenyl, fluorenyl, or anthryl). Typical aryl groups include, but are not limited to, radicals derived from benzene, naphthalene, anthracene, biphenyl, and the like. The aryl can be unsubstituted or optionally substituted with a substituent described below. For example, a phenyl moiety or group may be substituted with one or more substituents Rxwhere Rxis at the ortho-, meta-, or para-position, and X is an integer variable of 1 to 5.

[0082] The term "heteroaryl" refers to a monocyclic, bicyclic, or tricyclic ring system containing one, two, or three aromatic rings and containing at least one nitrogen, oxygen, or sulfur atom in an aromatic ring. The heteroaryl can be unsubstituted or substituted, for example, with one or more, and in particular one to three, substituents, as described in the definition of "substituted". Typical heteroaryl groups contain 2-20 carbon atoms in the ring skeleton in addition to the one or more heteroatoms, wherein the ring skeleton comprises a 5-membered ring, a 6-membered ring, two 5-membered rings, two 6-membered rings, or a 5-membered ring fused to a 6-membered ring. Examples of heteroaryl groups include, but are not limited to, 2H-pyrrolyl, 314-indolyl, 4H-quinolizinyl, acridinyl, benzo [b]thienyl, benzothiazolyl, β-carbolinyl, carbazolyl, chromenyl,cinnolinyl, dibenzo [b,d]furanyl, furazanyl, furyl, imidazolyl, imidizolyl, indazolyl, indolisinyl, indolyl, isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthyridinyl, oxazolyl, perimidinyl, phenanthridinyl, phenanthrolinyl, phenarsazinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, quinazolinyl, quinolyl, quinoxalinyl, thiadiazolyl, thianthrenyl, thiazolyl, thienyl, triazolyl, tetrazolyl, and xanthenyl. In one embodiment the term "heteroaryl" denotes a monocyclic aromatic ring containing five or six ring atoms containing carbon and 1, 2, 3, or 4 heteroatoms independently selected from nonperoxide oxygen, sulfur, and N(Z) wherein Z is absent or is H, 0, alkyl, aryl, or (Ci-C6)alkylaryl. In some embodiments, heteroaryl denotes an ortho-fused bicyclic heterocycle of about eight to ten ring atoms derived therefrom, particularly a benzo-derivative or one derived by fusing a propylene, trimethylene, or tetramethylene diradical thereto.

[0083] As used herein, the term "substituted" or “substituent” is intended to indicate that one or more (for example, in various embodiments, 1-10; in other embodiments, 1-6; in some embodiments 1, 2, 3, 4, or 5; in certain embodiments, 1, 2, or 3; and in other embodiments, 1 or 2) hydrogens on the group indicated in the expression using “substituted” (or “substituent”) is replaced with a selection from the indicated group(s), or with a suitable group known to those of skill in the art, provided that the indicated atom’s normal valency is not exceeded, and that the substitution results in a stable compound. Suitable indicated groups include, e.g., alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, hydroxyalkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, alkanoyl, alkoxycarbonyl, amino, alkylamino, dialkylamino, carboxyalkyl, alkylthio, alkylsulfinyl, and alkylsulfonyl. Substituents of the indicated groups can be those recited in a specific list of substituents described herein, or as one of skill in the art would recognize, can be one or more substituents selected from alkyl, alkenyl, alkynyl, alkoxy, halo, haloalkyl, hydroxy, hydroxyalkyl, aryl, heteroaryl, heterocycle, cycloalkyl, alkanoyl, alkoxycarbonyl, amino, alkylamino, dialkylamino, trifluoromethylthio, difluoromethyl, acylamino, nitro, trifluoromethyl, trifluoromethoxy, carboxy, carboxyalkyl, keto, thioxo, alkylthio, alkylsulfinyl, alkylsulfonyl, and cyano. Suitable substituents of indicated groups can be bonded to a substituted carbon atom include F, Cl, Br, I, OR’, OC(O)N(R')2, CN, CF3, OCF3, R', O, S, C(O), S(O), methylenedioxy, ethylenedioxy, N(R')2, SR', SOR', SO2R', SO2N(R')2, SO3R', C(0)R', C(O)C(O)R', C(O)CH2C(O), C(S)R’, C(0)0R’, 0C(0)R', C(O)N(R’)2, 0C(0)N(R')2, C(S)N(R')2, (CH2)0-2NHC(O)R', N(R')N(R')C(0)R', N(R’)N(R’)C(0)0R’, N(R’)N(R’)C0N(R’)2, N(R')S02R', N(R')SO2N(R’)2, N(R’)C(0)0R’, N(R')C(O)R', N(R')C(S)R', N(R')C(0)N(R')2, N(R')C(S)N(R’)2, N(C0R')C0R', N(0R’)R’, C(=NH)N(R')2, C(0)N(0R')R, or C(=N0R')R' wherein R’ can be hydrogen or a carbon-based moiety (e.g., (Ci-C6)alkyl), and wherein the carbon-based moietycan itself be further substituted. When a substituent is monovalent, such as, for example, F or Cl, it is bonded to the atom it is substituting by a single bond. When a substituent is divalent, such as 0, it is bonded to the atom it is substituting by a double bond; for example, a carbon atom substituted with 0 forms a carbonyl group, C=0.

[0084] Stereochemical definitions and conventions used herein generally follow S. P. Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., “Stereochemistry of Organic Compounds”, John Wiley & Sons, Inc., New York, 1994. The compounds of the invention may contain asymmetric or chiral centers, and therefore exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of the invention, including but not limited to, diastereomers, enantiomers and atropisomers, as well as mixtures thereof, such as racemic mixtures, which form part of the present invention. Many organic compounds exist in optically active forms, i.e., they have the ability to rotate the plane of plane-polarized light. In describing an optically active compound, the prefixes D and L, or R and S. are used to denote the absolute configuration of the molecule about its chiral center(s). The prefixes d and 1 or (+) and (-) are employed to designate the sign of rotation of plane-polarized light by the compound, with (-) or 1 meaning that the compound is levorotatory. A compound prefixed with (+) or d is dextrorotatory. For a given chemical structure, these stereoisomers are identical except that they are mirror images of one another. A specific stereoisomer may also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric mixture. A 50:50 mixture of enantiomers is referred to as a racemic mixture or a racemate (defined below), which may occur where there has been no stereoselection or stereospecificity in a chemical reaction or process.

[0085] The term “IC50” is generally defined as the concentration required to inhibit a specific biological or biochemical function by half, or to kill 50% of the cells in a designated time period, typically 24 hours.

[0086] Embodiments of the Technology.

[0087] 1. This disclosure provides a compound of Formula I:

[0088] Heteroaryl-Amido (I),

[0089] wherein,

[0090] Heteroaryl is represented by Formula IA1, IA2, IA3, or 1A4:

[0091]

[0092] wherein,

[0093] each J1is S, 0, or NRawherein Rais H or -(Ci-C6)alkyl;each J2is CRbwherein Rbis H or -(Ci-Ce)alkyl, or each J2is N;

[0094] each R1is H, halo, or — (Ci-C6)alkyl;

[0095] each Rlbis H, halo, or -(Ci-Ce)alkyl; and

[0096] each R2is H, halo, or -(Ci-Ce)alkyl;

[0097] Amido is represented by Formula IB1:

[0098]

[0099] Amin (IB1),

[0100] wherein,

[0101] Amin is heterocycloalkyl or N(RC)2 wherein each Rcis independently -(Ci-C6)alkyl;

[0102] L is absent or NRCwherein Rcis H or -(Ci-C6)alkyl;

[0103] R3is H or -(Ci-Ce)alkyl;

[0104] R4is H, halo, or unsubstituted or substituted -(Ci-Ce)alkyl; and

[0105] R5is H, -(Ci-Ce) alkyl, or halo provided that halo is not ortho to the amide moiety of Formula IB 1;

[0106] or salt thereof.

[0107] 1 a. The compound of embodiment 1, wherein the compound of Formula I is compound is not 3-chloro-A-(3-chloro-4-(4-methylpiperazin-l-yl)phenyl)benzo[b]thiophene-2-carboxamide. lb. The compound of embodiment 1, wherein J2of Formula IA1 is not CO and R4of Formula IB 1 is not Cl.

[0108] lc. The compound of embodiment 1 or la, wherein Amin of Formula IB 1 is not N-methylpiperazine.

[0109] ld. The compound of embodiment 1, wherein the compound of Formula I is compound is not 3-chloro-A-(4-(4-methylpiperazin-l-yl)phenyl)benzo[b]thiophene-2-carboxamide; oris not 3-chloro-A-(3-methyl-4-(4-methylpiperazin- 1 -yl)phenyl)benzo[b]thiophene-2-carboxamide; or is not 3-chloro-A-(4-(piperazin- 1 -yl)phenyl)benzo[b]thiophene-2-carboxamide.

[0110] 2. The compound of embodiment 1, wherein the Heteroaryl moiety of Formula I is represented by Formula IA1.

[0111] 3. The compound of embodiment 2, wherein the Heteroaryl moiety represented by Formula IA1 is Formula IA5:

[0112]

[0113] wherein Rbis H, halo, or -(Ci-C6)alkyl.

[0114] 4. The compound of embodiment of 3, wherein the Heteroaryl moiety represented by Formula IA5 is:

[0115]

[0116] 5. The compound of embodiment 1, wherein the Heteroaryl moiety of Formula I is represented by Formula IA2, wherein J1is S and J2is CH.

[0117] 6. The compound of embodiment 1, wherein the Amido moiety of Formula I is represented by Formula IB 2:

[0118]

[0119] Amin, wherein R4is H, Cl, CF3, or CH3.

[0120] 7. The compound of embodiment 1 or 6, wherein R5is halo or -(Ci-Ce)alkyl and R5is positioned meta relative to R4.

[0121] 8. The compound of any one of embodiments 1 or 6-7, wherein Amin is a 5- or 6-membered nitrogen-heterocycloalkyl.

[0122] 9. The compound of any one of embodiments 1 or 6-7, wherein Amin is piperidine, piperazine, morpholine, pyrrolidine, or dimethylamine.

[0123] 10. The compound of any one of embodiments 1 or 6-9, wherein Amin is positioned ortho relative to R4.

[0124] 11. The compound of any one of embodiments 1 or 6-9, wherein Amin is positioned meta relative to R4.

[0125] 12. The compound of any one of embodiments 1 or 6-9, wherein Amin is positioned para relative to R4.

[0126] The compound of any one of embodiments 1 or 6-9, wherein Amin is:

[0127]

[0128] In some embodiments the Amine is:

[0129]

[0130] 14. The compound of embodiment 1, wherein the compound is:

[0131]

[0132]

[0133]

[0134] or salt thereof.

[0135] 14a. A composition comprising a compound of any one of embodiments 1-14 and a pharmaceutically acceptable excipient.15. A method for treating a methicillin-resistant Staphylococcus aureus (MRS A) infection comprising administering to a subject in need thereof a combination of an antibiotic and an adjuvant comprising a compound of Formula I:

[0136] Heteroaryl-Amido (I),

[0137] wherein.

[0138] Heteroaryl is represented by Formula IA1, IA2, IA3, or 1A4:

[0139]

[0140] (IA4), wherein,

[0141] each J1is S, 0, or NRawherein Rais H or -(Ci-Ce)alkyl;

[0142] each J2is CRbwherein Rbis H or -(Ci-Cejalkyl, or each J2is N;

[0143] each R1is H, halo, or -(Ci-Cejalkyl;

[0144] each Rlbis H, halo, or -(Ci-Ce)alkyl; and

[0145] each R2is H, halo, or -(Ci-Cejalkyl;

[0146] Amido is represented by Formula IB1:

[0147]

[0148] Amin (IB1),

[0149] wherein,

[0150] Amin is heterocycloalkyl or N(RC)2 wherein each Rcis independently -(Ci-Cejalkyl;

[0151] L is absent or NRCwherein Rcis H or -(Ci-Cejalkyl;

[0152] R3is H or -(Ci-Cejalkyl;

[0153] R4is H, halo, or unsubstituted or substituted -(Ci-Cejalkyl; and

[0154] R5is H, — (Ci-Ce) alkyl, or halo provided that halo is not ortho to the amide moiety of Formula IB 1;

[0155] or a salt thereof; wherein the MRSA infection is thereby treated.

[0156] 16. The method of embodiment 15, wherein the antibiotic is oxacillin.

[0157] 17. The method of embodiment 15 or 16, wherein the MRSA infection is osteomyelitis. 18. The method of any one of embodiments 15-17, wherein the method mediates colonization of the cortical bone osteocyte lacuna-canalicular network (OLCN) in the subject.

[0158] 19. The method of any one of embodiments 15-18, wherein the compound inhibits penicillin binding protein 4 (PBP4) and / or penicillin binding protein 2a (PBP2a).

[0159] 20. The method of any one of embodiments 15-1, wherein the compound is:

[0160]

[0161] Results and Discussion.

[0162] Initial compound synthesis & screening. We initiated the study by screening a 30,000-member small molecule chemical compound library, which identified putative PBP4 inhibitor compound 1 (Chart 1). When dosed at 25 pM, 1 lowers the minimum inhibitory concentration (MIC) of BPR 16-fold in BPR-resistant, PBP4 over-expressor, S. aureus CRB. The same compound was investigated against a strain of MRS A that does not over-express PBP4.

[0163] Compound 1 does not impact S. aureus PBP4 expression, implying that compound 1 has potential as a PBP4 inhibitor. To further investigate 1, we began by synthesizing a library of compounds with altered benzothiophene head groups, phenyl cores, and piperazine tails. The first set of compounds in this library were synthesized utilizing a 1 -ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) hydrochloride mediated coupling with commercially available amines and carboxylic acids to yield products 2-13 (Scheme la,b).

[0164] Scheme la. General synthesis of benzothiophene analogs. Reagents and conditions for path A: (a) K2CO3, 1 -methylpiperazine; (b) Pd / C (10%), H2, MeOH, rt, 12 hr or SnCh, HC1; (c) appropriate benzothiophene-2-carboxylic acid or benzothiophene-3-carboxylic acid, EDC, DMAP, DCM, rt, 24 h.

[0165]

[0166] Scheme lb. General synthesis of benzothiophene analogs with commercially available anilines, (c) appropriate benzothiophene-2-carboxylic acid or benzothiophene-3 -carboxylic acid, commercially available amine, EDC, DMAP, DCM, rt, 24 h.

[0167]

[0168] Chart 2, Benzothiophene head analogs 2 - 13,

[0169]

[0170] We first measured the standalone antibacterial activity of each compound against MRSA 1556. Compounds 1-10 and 12-13 return an MIC value >200 pM and compound 11 returns an MIC of 100 pM (Table 1). After determining compounds 2-13 do not possess significant standalone antibacterial activity, the same compounds were tested for their adjuvant activity against the same strain in combination with oxacillin. Parent compound 1 returns an oxacillin MIC value of 0.25 pg / mL when dosed at 7.5 pM which is eight-fold lower than the reported Clinical Laboratory Standards Institute (CLSI) breakpoint value of 2 pg / mL for oxacillin in MRSA. The breakpoint concentration is a utilized as measure of whether a strain of bacteria is susceptible or resistant to given conditions.

[0171] Compounds 4-7 and 10 return MIC values within two-fold of the oxacillin MIC against MRSA 1556, overall indicating a loss of adjuvant activity compared to the parent. Compounds 4-7 possess a thiophene, indole, furan, and naphthalene ring respectively, which provides insight that the benzothiophene moiety could be essential for activity. Compound 10, which includes a 5-chlorobenzothiophene is also inactive, which could indicate the five-position is electronically disfavored for PBP binding. Compounds 2 and 3 are isosteres of the benzothiophene present in the parent. Compound 2, which lacks a three-position substituent returns comparable activity to the parent at 7.5 pM. However, 3 returns a sub-breakpoint MIC value at 30 pM, which is lost when tested at 15 pM. Overall, the isosteres do not return the same activity as the parent indicating there is possibly an electronic effect involved in the potential binding of PBP2a.Compound 8 returns an MIC value of 8 pg / mL at 60 pM, which is lost when tested at 30 pM, Given that oxacillin resistance is not completely restored, it is possible that substitutions at the six-position of the benzothiophene may have a minor impact on PBP binding. Compounds 9-13 have activity similar to the parent with MIC values ranging from 0.5 - 2 pg / mL. Compounds 9 and 13 have MIC values of 2 pg / mL at 7.5 and 5 pM, respectively (Table 1). Compound 13 lowers the MIC within the breakpoint value of oxacillin in MRSA 1556 at 5 pM, which is less than the active concentration of the parent compound.

[0172] Table 1. Standalone MIC and potentiation of oxacillin by head group analogs.

[0173]

[0174] Next, changes to the phenyl core and the piperazine core of the parent compound were investigated (Chart 3). Compounds 14 - 19, and 22 - 24 were synthesized via EDC-mediated coupling with commercially available carboxylic acids and anilines. Compounds 20, 21, and 25 were synthesized utilizing a three-step approach. Commercially available 4-fluoronitrobenzenes were reacted with 1 -methylpiperazine to yield various 1-methyl-4-(4-nitrophenyl)piperazines. Compounds 20 and 21 were reduced using 10% Pd / C and Eb to produce their corresponding anilines. Compound 25 was reduced using tin(II)chloride to produce the aniline. The final anilines were then reacted with 3-chlorobenzothiophene-2-carboxylic acid and EDC to afford the final product.Chart 3. Piperazine analogs 14 - 25.

[0175]

[0176] Compounds 14 - 18 and 24 exhibit a complete loss of activity in combination with oxacillin returning MIC values of 32 pg / mL (Table 2). Compounds 14 through 16, which contain the most drastic piperazine tail changes, result in a loss of activity. Compound 17 exhibits higher standalone toxicity than other compounds tested with a compound only MIC of 12.5 pM. When compound 17 is combined with oxacillin at 30% this concentration (3.25 pM), no oxacillin potentiation activity is observed. Compound 18 contains a piperidine instead of a piperazine, which results in a loss of oxacillin potentiation activity. Compound 22 contains the piperazine tail in the para position compared to the unsubstituted aromatic ring, while compound 23 shifts the piperazine tail to the meta position with regards to the aromatic ring and compound 24 shifts the piperazine to the ortho position. Compound 23 lowers the MIC to sub-breakpoint levels at 30 pM, where 22 and 24 do not lower the oxacillin to breakpoint concentrations at the highest concentration tested (60 pM).

[0177] Compounds 21, and 25 display moderate activity at high concentrations. Compound 20 lowers the MIC to sub-breakpoint levels when dosed at 15 pM, however it does have a lower standalone MIC value compared to the parent compound. Compound 20 replaces the chlorine on the aniline core with a methyl isostere. This methyl group may interact with a wider range of PBPs thus resulting in antibacterial activity. Compound 19 has a lower standalone MIC value of 25 pM; however, in combination with oxacillin at 7.5 pM (the same concentration tested as theparent), the oxacillin MIC is lowered to 0.5 pg / mL. Compound 19 contains an N-methyl piperidine ring. Between 18 and 19, the N-methyl nitrogen seems to be vital for adjuvant activity.

[0178] Table 2. Standalone MIC and potentiation of oxacillin by piperazine tail analogs.

[0179]

[0180] After several compounds with varied tails and head groups were synthesized and tested, four anilines were chosen to be synthesized and tested with benzothiophene-2-carboxylic acid based on their lack of activity with 3-chlorobenzothiophene-2-carboxylic acid (Chart 4).

[0181] Overall, we hoped to uncover activity that was not previously detected with the 3-chloro equivalents or the following aniline groups.

[0182] Chart 4. Piperazine analogs 26 - 29.

[0183]

[0184] r 28

[0185] Compound 26 maintains the same activity to compound 14 regardless of whether a chlorine or hydrogen is on the three-position of the benzothiophene (Table 3). It is possible that the missing portions of the piperazine rings contribute to activity and binding to PBP2a and the diamine in 26 and 14 might not conform to the binding pocket of PBP2a. Compound 27, which includes the morpholine ring has increased activity lowering the oxacillin MIC to the breakpoint.Compound 28 with the pyrrolidine ring shows increased activity compared to its 3 -chloro counterpart, but compared to the parent, the activity is not improved. Finally, compound 29, with a para piperazine, returned a complete lack of activity.

[0186] Table 3. Standalone MIC and potentiation of oxacillin by analogs 26 - 29.

[0187]

[0188] Further strain testing. We tested compounds against two additional MRSA strains, MRSA ATCC 43300 and MRSA AH- 1263, to determine if their activity is broad spectrum or strain specific. We uncovered that compounds 1, 2, 8, 9, 17, 19, and 20 lower the MIC below the oxacillin breakpoint against ATCC 43300 at concentrations <10 pM (Table 4). The activity of each compound shows that adjuvant activity for this library of compounds may not be strain specific (Table 4). As a result, compounds 1, 9, 13, and 17 each maintained sub-breakpoint activity in MRSA AH 1263 at concentrations comparable to the parent compound.

[0189] Table 4. Standalone MIC and potentiation of library in MRSA ATCC 43300 and MRSA AH- 1263.

[0190]

[0191]

[0192] Hybrid compound synthesis and testing. As a result of our initial biological screening, several hybrid compounds were synthesized. The aniline side chain of compound 19 was reacted with several head groups where augmented oxacillin activity was observed (Chart 5). Overall, we aim that the hybrid compounds will be additive in their activity.

[0193] Chart 5. Hybrid analogs 30 - 33.

[0194]

[0195] These four compounds were tested in combination with oxacillin against MRSA 1556, MRSA 43300, and MRSA AH-1263 and consistently showed that compounds 30 and 33 lower the MIC within 2-fold of the breakpoint value at various concentrations. However, the most promising combination(s) are compound 30 at 10 pM against MRSA 1556 and 33 at 10 pM in MRSA ATCC 43300 (Table 5).

[0196] Table 5. Standalone MIC and potentiation of hybrid compounds.

[0197]

[0198] MRSAAH 1263

[0199]

[0200] All previous potentiation assays were tested with oxacillin as a way to predict adjuvant interaction or binding with PBP2a. As a result, several compounds were tested in another strain of MRSA, MRSA CRB, which is a mecA negative and PBP4 over-expressing strain of MRSA. The mecA gene codes for the PBP2a protein and potentiation with CRB and ceftobiprole (BPR) was tested to determine if compounds potentially bind to PBP4.

[0201] Several compounds tested have comparable activity to the parent compound at lower concentrations, including compounds that potentially bind PBP4 (Table 6). Largely, this is important for dual activity of the desired adjuvant.

[0202] Table 6. Standalone MIC and potentiation of listed compounds with CRB and BPR.

[0203]

[0204] Exploration of a Benzo thiophene Scaffold for Use as Adjuvants with f -Lactam Antibiotics against Methicillin-Resistant Staphylococcus aureus.

[0205] Rising antibiotic resistance coupled with diminishing investment in antibiotic development has led to limited treatment options for multi-drug-resistant bacterial infections. Penicillin binding protein 2a (PBP2a) is a key determinant of resistance to many P-lactam antibiotics in methicillin-resistant Staphylococcus aureus (MRSA), while over-expression of PBP4 mediates resistance to fifth-generation cephalosporins. We previously identified benzothiophene NDM-335 as an inhibitor of PBP4 that overcomes PBP4 mediated resistance to ceftobiprole and have shown that other PBP4 inhibitor scaffolds can be tuned to overcome PBP2a-mediated resistance. Based upon this precedent, we conducted a structure activityrelationship (SAR) study on the NDM-335 scaffold to uncover compounds that overcome PBP2a-mediated oxacillin resistance in MRSA, with the lead compound lowering the minimum inhibitory concentration 32-fold at 5 pM. Further development of this new adjuvant lead could potentially deliver a new combination therapy for treating MRSA infections.

[0206] Penicillin binding proteins (PBPs) are transpeptidases / transglycosylases that play a role in the formation of the peptidoglycan component of the bacterial cell wall. S. aureus encodes four native PBPs; two essential (PBP1 and PBP2) and two non-essential (PBP3 and PBP4). While resistance to P-lactams in MRSA predominantly occurs through the non-native PBP2a (encoded by mecA), which has a lower affinity for most P-lactams than native PBPs, PBP2a-independent P-lactam resistance has also been reported (Antimicrob Agents Chemother. 2016;60(7):3934-41). This latter resistance is derived from the overexpression of PBP4 and / or a PBP4 variant, and confers resistance to the fifth-generation cephalosporins, ceftobiprole (BPR) and ceftaroline, which are otherwise active against MRSA. This discovery prompted us to screen for potentiators of BPR in a PBP4 overexpressing strain of. S', aureus to identify potential inhibitors of PBP4. One hit from this screen was the phenyl urea ChemBridge 9314848, which inhibits binding of a fluorescently labeled penicillin molecule (Bocillin-FL) to PBP4 and, interestingly, PBP2a.

[0207] Compound 9314848 also potentiates P-lactams against MRSA strains with PBP2a-derived resistance, and analog synthesis led to the identification of compounds with increased activity with select penicillins and cephalosporins.

[0208]

[0209] Structure of 9314848 (left) and NDM-335 (right).

[0210] Another compound identified from the screen for PBP4 inhibitors was NDM-335 (ChemBridge 7974147). At 25 pM, NDM-335 lowers the minimum inhibitory concentration (MIC) of BPR to 8 pg / mL against the BPR-resistant, PBP4 over-expressor CRB without affecting expression of pbp4. CRB is a derivative of the MRSA strain COL that lacks the mecA gene coding for PBP2a, and over-expresses PBP4 leading to broad resistance to b-lactams, including fifth generation cephalosporins. Given that ChemBridge 9314848 could be tuned to reduce b-lactam resistance in PBP2a-dependent strains with normal PBP4 expression levels, we elected to further explore the potential of NDM-335 and analogs as antibiotic adjuvants targeting PBP2a-dependent resistance.Results and Discussion.

[0211] We first resynthesized NDM-335 via a 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) hydrochloride mediated coupling of commercially available 3-chlorobenzothiophene-2-carboxylic acid and 3-chloro-4-(4-methylpiperazin-l-yl)aniline (Scheme 2). We further verified the structure of NDM-335 by solving its crystal structure.

[0212] Scheme 2. (a) EDC, DMAP, DCM, rt, 24 h, 49.5% yield.

[0213]

[0214] NDM-335

[0215] We first determined the standalone MIC of NDM-335 against the USA300 strain MRSA BAA-1556 (PBP2a / normal PBP4 expression) under standard microdilution assay conditions to be >200 pM. We began a series of oxacillin potentiation assays, which are commonly used to identify other inhibitors of PBP2a related pathways. At 60 pM (<30% standalone MIC), NDM-335 lowers the oxacillin MIC against this strain from 32 pg / mL to 0.125 pg / mL (256-fold). Against MRSA, the Clinical Laboratory Standards Institute (CLSI) breakpoint for oxacillin is 2 pg / mL. We sequentially performed a dose-response study to determine the lowest concentration of NDM-335 that lowers the oxacillin MIC to or below the clinical breakpoint, and term this the adjuvant’s minimum effective concentration (MEC). Against BAA-1556, at 7.5 pM, NDM-335 lowers the oxacillin MIC to 0.25 pg / mL, while at 3.75 pM, it suppresses the MIC to 8 pg / mL (Table 7), indicating the MEC lies between 7.5 and 3.75 pM. We then evaluated NDM-335 against two additional MRSA strains: ATCC 43300 and AH-1263 (standalone oxacillin MICs of 32 pg / mL for each strain), both of which also harbor the mecA gene and show normal PBP4 expression levels. NDM-335 lowers the oxacillin MIC to 0.5 pg / mL at 5 pM in ATCC 43300, and to 0.25 pg / mL at 7.5 pM in AH-1263. As a control, we measured potentiation of BPR by NDM-335 against BAA- 1556. In this strain, the BPR MIC is 1 pg / mL, and this is only reduced four-fold in the presence of 12.5 pM (and concentrations up to 200 pM) NDM-335, indicating strong specificity for PBP2a-dependent resistance.Table 7. Oxacillin MICs against MRSA ATCC BAA-1556, MRSA 43300, and MRSA AH-1263 in the presence and absence of NDM-335.

[0216]

[0217] With these promising results, we initiated a structure activity relationship (SAR) study of the benzothiophene region of NDM-335 to determine whether compounds with enhanced adjuvant activity could be identified. To this end, we synthesized a library of compounds in which the benzothiophene was replaced with alternative heterocycles (or a naphthyl ring), while conserving the 3-chloro-4-(4-methylpiperazine) moiety. Following the synthetic route outlined in Scheme 2, the indole, 3-chloroindole, benzothiazole, furan, benzofuran, and naphthalene derivatives (Chart 6) were synthesized from the respective commercially available carboxylic acids. Indole, 3-chloroindole, benzothiazole, benzofuran, and naphthalene were selected for their structural similarities to benzothiophene, and to analyze the impact of altering the heteroatom of the benzothiophene head group. The furan was chosen to assess the necessity of the benzyl ring and the sulfur atom.Chart 6: Benzothiophene heterocycle substitutions.

[0218]

[0219] The 3 -chlorobenzofuran (NDM-713) analog required a more complex synthesis (Scheme 3), starting with subjecting benzofuran-3(277)-one to Vilsmeier-Haack conditions to provide 3- chlorobenzofuran-2-carbonitrile, 1. The nitrile was then treated with sodium hydroxide to provide key intermediate 2, which was then reacted with 3-chloro-4-(4-methylpiperazin-l- yljaniline via an EDC-mediated coupling to yield NDM-713. To access the 2-chloronapthalene (NDM-712) derivative (Scheme 3), 3-amino-2-naphthoic acid was subjected to Sandmeyer conditions to provide 3-chloro-2-naphthoic acid, 3. 3-Chloro-2-naphthoic acid was then reacted with 3-chloro-4-(4-methylpiperazin-l-yl)aniline via an EDC coupling to provide amide NDM- 712.

[0220] Scheme 3. (a) POCl3, DMF 0 °C - rt 1hr, NH2OH 0 °C - rt, 1 hr, quant, yield, (b) NaOH, EtOH: H2O, 100 °C, 2 hr, 14% yield, (c) EDC, DMAP, DCM, rt, 24 hr. (d) 3M HCl, NaNO2, CuCl 0 °C, 1 hr, 17% yield, (e) EDC, DMAP, DCM, rt, 24 hr, 31% yield.

[0221]

[0222] Table 8. Oxacillin MICs against MRS A ATCC BAA- 1556, MRS A ATCC 43300, and MRS A AH-1263 in the presence of benzothiophene analogs.

[0223]

[0224]

[0225] The stand-alone MIC of each compound was first determined against the same three MRSA strains described above (Table 8), with all compounds, except the 3 -chloroindole derivative NDM-704, returning MICs of 100 to >200 pM. Due to low solubility of NDM-704 in stock solution of DMSO, it was tested at ten-fold lower starting concentrations and returned astand-alone MIC greater than 20 pM in BAA-1556, 43300, and AH-1263. Oxacillin MICs in the presence of each analog are summarized in Table 8. The naphthyl (NDM-365), indole (NDM-406), and furan (NDM-407) derivatives fail to potentiate oxacillin against BAA- 1556 and AH-1263, returning unchanged oxacillin MICs of 32 pg / mL at 60 pM. Against 43300, NDM-365 and NDM-407 exhibit minimal activity, lowering the oxacillin MIC only four- fold to 8 pg / mL at 60 pM. Against this same strain, NDM-406 lowers the oxacillin MIC 32-fold to 1 pg / mL at 60 pM, and 64-fold to 0.5 pg / mL at 30 pM, but lost significant activity at 15 pM with an oxacillin MIC of 4 pg / mL (eight-fold reduction). Against BAA- 1556, the benzofuran derivative (NDM-511) lowers the oxacillin MIC 32-fold to 1 pg / mL at 60 pM, and four-fold (8 pg / mL) at 30 pM. Against 43300, NDM-511 returns an oxacillin MIC of 0.25 pg / mL at 60 pM, which increases to 4 pg / mL at 30 pM. Against AH-1263, NDM-511 suppresses the oxacillin MIC to 0.5 pg / mL at 60 pM, which increases to 8 pg / mL at 30 pM. Against BAA-1556 and 43300, NDM-704 is inactive at 6 pM, returning oxacillin MICs of 16 pg / mL, an insignificant two-fold drop from the standalone oxacillin MIC. In AH-1263, NDM-704 delivers an eight- fold reduction in oxacillin MIC to 4 pg / mL at 6 pM. The 2-chloronaphthyl derivative (NDM-712) lowers the oxacillin MIC to 16 pg / mL and 8 pg / mL at 60 pM, in BAA-1556 and 43300, respectively. NDM-712 reduces the oxacillin MIC to the breakpoint of 2 pg / mL at 60 pM in AH-1263. and to 4 pg / mL at 30 pM. The 3 -chlorobenzofuran derivative (NDM-713) suppresses the oxacillin MIC to 0.125 pg / mL, 0.125 pg / mL, and 0.25 pg / mL against BAA-1556, 43300, and AH-1263, respectively, at 30 pM. At 15 pM, the oxacillin MIC increases to 32 pg / mL, 16 pg / mL, and 16 pg / mL against these three strains. Finally, the benzothiazole derivative (NDM-428) lowers the MIC of oxacillin below the breakpoint at 5 pM in BAA-1556 (to 2 pg / mL) and at 7.5 pM in AH-1263 (to 0.5 pg / mL) but interestingly is not active in 43300 (returning an oxacillin MIC of 16 pg / mL). From this, it appears that the presence of a sulfur atom at the one-position of the heterocycle is important for oxacillin adjuvant activity.

[0226] Based upon the importance of the sulfur atom, we next investigated compounds with various sulfur containing heterocycles (Chart 7). Each derivative was synthesized from the respective carboxylic acid using the approach outlined in Scheme 2. Analogs synthesized include: NDM-366 that contains a thiophene, NDM-702 with a 3-chlorothiophene, and NDM-547 that harbors a benzothiophene group attached at the 3 -position, rather than the 2-position as seen in NDM-335.Chart 7. Sulfur-containing heterocycle analogs.

[0227]

[0228] Table 9. Oxacillin MICs against MRSA ATCC BAA-1556, MRSA ATCC 43300, and MRSA AH- 1263 in the presence of benzothiophene analogs.

[0229]

[0230] The thiophene derivatives NDM-366 and NDM-702 have standalone MICs greater than 200 pM against all three strains, while NDM-547 exhibits a standalone MIC of 100 pM against each strain (Table 9). NDM-702 is inactive at 60 pM, returning oxacillin MICs of 16 pg / mL against all three strains. NDM-366 is inactive against BAA-1556, and AH-1263, and only lowers the oxacillin MIC four-fold to 8 pg / mL against 43300 at 60 pM. NDM-547 returns an oxacillin MIC of 0.5 pg / mL at 30 pM in BAA-1556, but loses activity at lower concentrations, only reducing the oxacillin MIC to 4 pg / mL at 15 pM. Against 43300, NDM-547 lowers the oxacillin MIC to 1 pg / mL at 15 pM, but fails to reach breakpoint levels at 10 pM, returning an MIC of 4 pg / mL. In AH-1263, NDM-547 lowers the MIC of oxacillin to 0.5 pg / mL at 30 pM, and to 16 u <> / ml. at 15 n M. In aggregate, these data underscore the importance of a benzothiophene motiffor activity, with connection at the C-2 position delivering the highest activity. To follow up on this observation, additional C-2 substituted benzothiophenes were synthesized (Chart 8) again via the route shown in Scheme 2. These include: the unsubstituted analog (NDM-400), 5-methylbenzothiophene (NDM-427), 5 -chlorobenzothiophene (NDM-419), 6-chlorobenzo-thiophene (NDM-703), 3 -methylbenzothiophene (NDM-343), and 6- methylbenzothiophene (NDM-408).

[0231] Chart 8: Substituted benzothiophene analogs.

[0232]

[0233] Standalone MIC and adjuvant activity for these analogs is summarized in Table 10. The 5-chlorobenzothiophene analog NDM-419 is inactive at 60 pM against BAA-1556 and AH-1263, while it is only moderately active against 43300, returning oxacillin MICs of 32 pg / mL, 16 pg / mL, and 8 pg / mL, respectively. The 6-chloro derivative NDM-703 exhibits a similar lack of activity, returning oxacillin MICs of 16 pg / mL, 8 pg / mL, and 16 pg / mL against BAA-1556, 43300, and AH-1263, respectively at 60 pM. The 6-methyl derivative NDM-408 is moderately active against BAA-1556 and AH-1263, lowering the oxacillin MIC four-fold to 8 pg / mL at 60 pM; however, it exhibits greater activity against 43300, lowering the oxacillin MIC to 2 pg / mL at 5 pM. The unsubstituted derivative NDM-400 lowers the oxacillin MIC to 1 pg / mL at 7.5 pM and 2 pg / mL at 5 pM in BAA-1556 and 43300, respectively, and to 0.5 pg / mL at 15 pM against AH-1263. The 5-methyl derivative NDM-427 retains activity at 7.5 pM against all three strains, lowering the oxacillin MIC to 2 pg / mL. As a result of the initial SAR study, the parent NDM-335, the unsubstituted benzothiophene NDM-400, the 6-methylbenzothiophene NDM-408, the 5-methylbenzothiophene NDM-427, and the benzothiazole NDM-428 were subject to further investigation. NDM-335, NDM-408, NDM-427, and NDM-428 were chosen as lead compounds because they potentiate oxacillin at concentrations of 10 pM or lower in at least two out of the three strains tested. While NDM-400 does not achieve this same standard, we chose it as a lead compound due to its activity at 5 pM in MRSA 43300 and 15 pM in MRSA AH-1263.Table 10, Oxacillin MICs against MRS A ATCC BAA- 1556, MRSA ATCC 43300, and MRSA AH- 1263 in the presence of benzothiophene analogs.

[0234]

[0235]

[0236] Lead compounds were tested against the methicillin sensitive 5. aureus (MSSA) strain ATCC 29213 as a control (Table 11). MSSA 29213 lacks PBP2a, leading us to predict that potentiation activity would be lost. NDM-400, NDM-408, NDM-427, and NDM-428 lower the MIC of oxacillin to 0.125 pg / mL at 60 pM, which is two-fold lower than the standalone oxacillin MIC of 0.25 pg / mL in MSSA 29213. MIC changes of two-fold are considered statistically insignificant, thus strongly indicating that the potentiation activity is related to PBP2a, or other regulatory networks involved in PBP2a-mediated resistance.

[0237] Table 11. Oxacillin MICs against MSSA 29213 in the presence of lead benzothiophene analogs.

[0238]

[0239] Following the study of benzothiophene derivatives in combination with oxacillin, activity of lead compounds with two additional P-lactams: penicillin G (Table 12), and the second-generation cephalosporin, cefoxitin (Table 13) was explored. In BAA-1556 and MRSA 43300, three of the five compounds (NDM-408, NDM-427, and NDM-428) did not reduce the MIC of penicillin G to its clinical breakpoint of 0.125 pg / mL at 60 pM (Table 13). NDM-335 lowers the penicillin G MIC to 0.0625 at 60 pM, 30 pM, and 15 pM, but fails to achieve breakpoint levels at 10 pM. NDM-400 returns a penicillin G MIC of 0.015625 pg / mL at 60 pM and 0.125 pg / mL at 30 pM but fails to achieve breakpoint levels at 15 pM. In MRSA 43300, NDM-335, NDM-408, NDM-427, and NDM-428 do not achieve breakpoint level MICs when dosed at 60 pM.NDM-400 lowers the penicillin G MIC to 0.03125 pg / mL at 60 pM, but the MIC increases to 0.5 pg / mL when dosed at 30 pM. Against MRSA AH-1263, NDM-408, NDM-427, and NDM-428 return MICs greater than the penicillin G breakpoint of 0.125 pg / mL at 60 pM. NDM-335 and NDM-400 return penicillin G MICs of 0.125 pg / mL and 0.015625 pg / mL respectively at 60 pM. Both compounds return penicillin MICs of 0.125 pg / mL at 30 pM, but activity is lost at 15 pM. At 15 pM, NDM-335 and NDM-400 return penicillin G MICs of 4 pg / mL.

[0240] Table 12. Penicillin G MICs MRS A ATCC BAA- 1556, MRS A ATCC 43300, and MRS A AH- 1263 in the presence of benzothiophene analogs.

[0241]

[0242]

[0243] Lead compounds were tested with cefoxitin. Against MRSA BAA-1556, NDM-335, NDM-408, NDM-427, and NDM-428 fail to lower the cefoxitin MIC to its clinical breakpoint level of 4 pg / mL. NDM-335 lowers the cefoxitin MIC to 0.125 pg / mL at 60 pM, and 16 pg / mL at 30 pM. Against MRSA 43300, NDM-335, NDM-408, NDM-427, and NDM-428 fail to lower the cefoxitin MIC to breakpoint levels. NDM-400 lowers the cefoxitin MIC to 0.5 pg / mL at 60 pM and 16 pg / mL at 30 pM, showing a loss of activity at 30 pM. In MRSA AH- 1263, NDM-400, NDM-408, NDM-427, and NDM-428 fail to lower the cefoxitin MIC to breakpoint levels. Taken together, these results are similar to other adjuvants we have developed, where there appears to be an optimal antibiotic partner within the general antibiotic class.

[0244] Table 13. Cefoxitin MICs MRSA ATCC BAA-1556, MRSA ATCC 43300, and MRSA AH-1263 in the presence of benzothiophene analogs.

[0245]

[0246]

[0247] Growth curves were then constructed for NDM-335, NDM-400, and NDM-427 using MRSA ATCC 43300 as the test strain (Figure 1, Figure 2, Figure 3). Each compound at its MEC in combination with oxacillin at the breakpoint concentration (2 pg / mL) was examined, along with 2X and 4X this dosing. Based on the changes in colony forming units (CFUs), the combination of NDM-335, NDM-400, and NDM-427 with oxacillin was determined to be bacteriostatic.

[0248] S. aureus codes for a repertoire of two component regulatory systems (TCS), including VraRS, ArlRS, WalKR, BlaIR, GraRS, SaeRS, that have been shown to directly or indirectly modulate resistance to cell wall active antibiotics. Thus, to begin a preliminary investigation into the mechanism of action, lead compounds were examined against a panel of deletion strains that each have one of the 15 nonessential. S', aureus two component systems deleted, as well as a mecA transposon mutant, and activity was compared to that against the parent (MRSA AH-1263). First, the oxacillin MIC was determined for each strain (Table 14). Four strains have significantly lower oxacillin MICs than the parent strain, indicating involvement of these gene products in oxacillin resistance. AH 2360 (ΔgraRS), AH 2087 (ΔvraRS) AH 2090 (ΔkdpDE), and AH 5929 (mecA: Tn mutant) have oxacillin MICs of 0.5 pg / mL (64-fold), 4 pg / mL (eight-fold), 8 pg / mL (four- fold), and 0.25 pg / mL (128-fold), respectively. In all four strains, each compound has a standalone MIC >200 pM. Against the graRS mutant, no compounds potentiate the activity of oxacillin (MIC lowered no more than two-fold), suggesting that GraRS is required for adjuvant activity. Against the vraRS deletion strain AH 2087, all compounds further potentiate the activity of oxacillin, implying that the VraRS regulatory system is not the target of this series of compounds. Against the kdpDE deletion strain AH 2090, only NDM-428 does not further potentiate oxacillin (MIC lowered only two-fold), indicating that KdpDE is not the general target for this series of compounds, but further investigation is required to determine if it plays a role in the activity of NDM-428. Finally, against the mecA transposon mutant AH 5929, no compound further potentiates the activity of oxacillin, suggesting that PBP2a is also required for adjuvant activity. In aggregate, this indicates that the potential targets for these compounds are involved in the GraRS two component signaling system and / or PBP2a (in

[0249] both cases either direct binding or downregulation of the genes).Table 14, Lead compounds against a mecA transposon mutant and two TCS deletion strains.

[0250]

[0251] To follow up on these studies, we performed RT-PCR to determine if the mechanism of the compounds was underpinned by downregulation of mecA, graR, or graS using NDM-335 and BAA-1556 as our representative adjuvant / strain combination (Figure 4). At all concentrations studied (6.25 pM-50 pM), no statistically significant downregulation of any of the genes wasobserved, indicating that neither the regulatory genes driving transcription of mecA, nor the genes encoding the GraRS TCS are the targets of this compound.

[0252] To establish the therapeutic index (TI) of lead compounds, their effect on viability of the hepatocellular carcinoma cell line, HepG2, was determined. The TI for conventional antibiotic development is defined as (mammalian cell CC50) / (antibiotic MIC), with a TI >50 desirable for further development. Because adjuvants, by definition, are typically non-toxic to bacteria, we define adjuvant TI as (mammalian cell CC50) / MEC. The CC50 was determined for the five lead compounds (Table 15). The parent compound, NDM-335, has a CC50 of 96.8 pM, an active concentration of 7.5 pM, and a TI of 12.9. NDM-400 returns a CC50 of 145.9 pM, an active concentration ranging from 5 pM to 7.5 pM across the three strains, resulting in a TI ranging from 19.5 to 29.2. NDM-408 has a CC50 of 81.4 pM, an active concentration of 5 pM, and a TI of 16.3. NDM-427 returns a CC50 of 81.4 pM, an active concentration of 7.5 pM, and a TI of 10.9. Finally, NDM-428 has a CC50 of 179.6 pM, an active concentration ranging from 5 pM to 7.5 pM, and a TI ranging from 24.0 to 35.9. While none of the compounds return a TI > 50, all but one compound (NDM-427) has an increased TI

[0253] compared to the parent compound.

[0254] Table 15. HepG2 CC50s (μM) and TIs.

[0255]

[0256] Conclusion.

[0257] Through an initial SAR study on benzothiophene NDM-335, we identified several novel compounds that lower the MIC of oxacillin to or below the CLSI breakpoint of 2 pg / mL against at least one MRS A strain at 10 pM or lower. Structural trends revealed a strong correlation between activity and sulfur-containing heterocycles, with benzothiophene and benzothiazole motifs providing the most robust adjuvant activity. Substitution patterns within the benzothiophene ring significantly influence potency and strain-based activity, underscoring the sensitivity of this scaffold to modifications. Activity was largely restricted to oxacillin and penicillin G, with limited potentiation of cefoxitin, suggesting antibiotic-class selectivity consistent with PBP resistance mechanisms. Preliminary mechanistic studies further support a role for PBP2a in the observed adjuvant activity. Loss of potentiation in a mecA transposon mutant and in a graRS deletion strain indicates that PBP2a and GraRS-mediated regulation are required for activity. Follow up RT-PCR analysis has indicated neither controlling mecA expression, nor the genes encoding the GraRS TCS are the targets of these compounds. We arecurrently purifying PBP2a from BAA-1556 to perform both binding and inhibition assays to further establish the mechanism of action of these compounds and will be reported in due course. This work validates the benzothiophene scaffold as a promising foundation for B-lactam adjuvant development and provides a framework for future efforts aimed at enhancing potency, maintaining appropriate safety metrics, and defining mechanistic activity. Compared to our previously identified PBP2a-dependent oxacillin adjuvants, the benzothiophenes appear more promising than the phenyl urea scaffold for further development as they remain active in potentiation assays at lower concentrations (10 pM or lower), while phenyl urea derivatives are active at high concentrations (60 pM).

[0258] Pharmaceutical Formulations.

[0259] The compounds described herein can be used to prepare therapeutic pharmaceutical compositions, for example, by combining the compounds with a pharmaceutically acceptable diluent, excipient, or carrier. The compounds may be added to a carrier in the form of a salt or solvate. For example, in cases where compounds are sufficiently basic or acidic to form stable nontoxic acid or base salts, administration of the compounds as salts may be appropriate.

[0260] Examples of pharmaceutically acceptable salts are organic acid addition salts formed with acids that form a physiologically acceptable anion, for example, tosylate, methanesulfonate, acetate, citrate, malonate, tartrate, succinate, benzoate, ascorbate, and a-ketoglutarate. Suitable inorganic salts may also be formed, including hydrochloride, halide, sulfate, nitrate, bicarbonate, and carbonate salts.

[0261] Pharmaceutically acceptable salts may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid to provide a physiologically acceptable ionic compound. Alkali metal (for example, sodium, potassium or lithium) or alkaline earth metal (for example, calcium) salts of carboxylic acids can also be prepared by analogous methods.

[0262] The compounds of the formulas described herein can be formulated as pharmaceutical compositions and administered to a mammalian host, such as a human patient, in a variety of forms. The forms can be specifically adapted to a chosen route of administration, e.g., oral or parenteral administration, by intravenous, intramuscular, topical or subcutaneous routes.

[0263] The compounds described herein may be systemically administered in combination with a pharmaceutically acceptable vehicle, such as an inert diluent or an assimilable edible earner. For oral administration, compounds can be enclosed in hard or soft shell gelatin capsules, compressed into tablets, or incorporated directly into the food of a patient's diet. Compounds may also be combined with one or more excipients and used in the form of ingestible tablets,buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations typically contain at least 0.1 % of active compound. The percentage of the compositions and preparations can vary and may conveniently be from about 0.5% to about 60%, about 1% to about 25%, or about 2% to about 10%, of the weight of a given unit dosage form. The amount of active compound in such therapeutically useful compositions can be such that an effective dosage level can be obtained.

[0264] The tablets, troches, pills, capsules, and the like may also contain one or more of the following: binders such as gum tragacanth, acacia, com starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; and a lubricant such as magnesium stearate. A sweetening agent such as sucrose, fructose, lactose or aspartame; or a flavoring agent such as peppermint, oil of Wintergreen, or cherry flavoring, may be added. When the unit dosage form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier, such as a vegetable oil or a polyethylene glycol. Various other materials may be present as coatings or to otherwise modify the physical form of the solid unit dosage form. For instance, tablets, pills, or capsules may be coated with gelatin, wax, shellac or sugar and the like. A syrup or elixir may contain the active compound, sucrose or fructose as a sweetening agent, methyl and propyl parabens as preservatives, a dye and flavoring such as cherry or orange flavor. Any material used in preparing any unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed. In addition, the active compound may be incorporated into sustained-release preparations and devices.

[0265] The active compound may be administered intravenously or intraperitoneally by infusion or injection. Solutions of the active compound or its salts can be prepared in water, optionally mixed with a nontoxic surfactant. Dispersions can be prepared in glycerol, liquid polyethylene glycols, triacetin, or mixtures thereof, or in a pharmaceutically acceptable oil. Under ordinary conditions of storage and use, preparations may contain a preservative to prevent the growth of microorganisms.

[0266] Pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions, dispersions, or sterile powders comprising the active ingredient adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes. The ultimate dosage form should be sterile, fluid and stable under the conditions of manufacture and storage. The liquid earner or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof. The proper fluidity can be maintained, for example, by theformation of liposomes, by the maintenance of the required particle size in the case of dispersions, or by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and / or antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers, or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by agents delaying absorption, for example, aluminum monostearate and / or gelatin.

[0267] Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in the appropriate solvent with various other ingredients enumerated above, as required, optionally followed by filter sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation can include vacuum drying and freeze-drying techniques, which yield a powder of the active ingredient plus any additional desired ingredient present in the solution.

[0268] For topical administration, compounds may be applied in pure form, e.g., when they are liquids. However, it will generally be desirable to administer the active agent to the skin as a composition or formulation, for example, in combination with a dermatologically acceptable carrier, which may be a solid, a liquid, a gel, or the like.

[0269] Useful solid carriers include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina, and the like. Useful liquid earners include water, dimethyl sulfoxide (DMSO), alcohols, glycols, or water-alcohol / glycol blends, in which a compound can be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants.

[0270] Adjuvants such as fragrances and additional antimicrobial agents can be added to optimize the properties for a given use. The resultant liquid compositions can be applied from absorbent pads, used to impregnate bandages and other dressings, or sprayed onto the affected area using a pumptype or aerosol sprayer.

[0271] Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses, or modified mineral materials can also be employed with liquid carriers to form spreadable pastes, gels, ointments, soaps, and the like, for application directly to the skin of the user.

[0272] Examples of dermatological compositions for delivering active agents to the skin are known to the art; for example, see U. S. Patent Nos. 4,992,478 (Geria), 4,820,508 (Wortzman), 4,608,392 (Jacquet et al.), and 4,559,157 (Smith et al.). Such dermatological compositions can be used in combinations with the compounds described herein where an ingredient of such compositions can optionally be replaced by a compound described herein, or a compound described herein can be added to the composition.Useful dosages of the compounds described herein can be determined by comparing their in vitro activity, and in vivo activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U. S. Patent No. 4,938,949 (Borch et al.). The amount of a compound, or an active salt or derivative thereof, required for use in treatment will vary not only with the particular compound or salt selected but also with the route of administration, the nature of the condition being treated, and the age and condition of the patient, and will be ultimately at the discretion of an attendant physician or clinician.

[0273] In general, however, a suitable dose will be in the range of from about 0.5 to about 100 mg / kg, e.g., from about 10 to about 75 mg / kg of body weight per day, such as 3 to about 50 mg per kilogram body weight of the recipient per day, preferably in the range of 6 to 90 mg / kg / day, most preferably in the range of 15 to 60 mg / kg / day.

[0274] The compound is conveniently formulated in unit dosage form; for example, containing 5 to 1000 mg, conveniently 10 to 750 mg, most conveniently, 50 to 500 mg of active ingredient per unit dosage form. In one embodiment, the invention provides a composition comprising a compound of the invention formulated in such a unit dosage form.

[0275] The compound can be conveniently administered in a unit dosage form, for example, containing 5 to 1000 mg / m2, conveniently 10 to 750 mg / m2, most conveniently, 50 to 500 mg / m2of active ingredient per unit dosage form. The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day. The sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations.

[0276] The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day. The sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations; such as multiple inhalations from an insufflator or by application of a plurality of drops into the eye.

[0277] The compounds described herein can be effective antibiotic adjuvants and have higher potency and / or reduced toxicity as compared to an antibiotic alone.

[0278] The invention provides therapeutic methods of treating a MRSA infection in a mammal, which involve administering to a mammal having a MRSA infection an effective amount of a compound or composition described herein. A mammal includes a primate, human, rodent, canine, feline, bovine, ovine, equine, swine, caprine, bovine and the like.The ability of a compound of the invention to treat a MRSA infection may be determined by using assays well known to the art. For example, the design of treatment protocols, toxicity evaluation, data analysis, quantification of bacteria cell kill are known. In addition, ability of a compound to treat a MRSA infection may be determined using the Tests as described below.

[0279] The following Examples are intended to illustrate the above invention and should not be construed as to narrow its scope. One skilled in the art will readily recognize that the Examples suggest many other ways in which the invention could be practiced. It should be understood that numerous variations and modifications may be made while remaining within the scope of the invention.

[0280] EXAMPLES

[0281] Example 1. Experimental. The compounds in Table 16 are designed to be paired with the appropriate antibiotic to resensitize bacteria to antibiotics they are resistant to. Such compounds may also be used as prophylactics to prevent bone infections.

[0282]

[0283]

[0284] 48 501.119WO1

[0285] ND P25-040-PCT

[0286]

[0287] 49 501.119WO1

[0288] ND P25-040-PCT

[0289]

[0290] 50 501.119WO1

[0291] ND P25-040-PCT

[0292]

[0293] 51 501.119WO1

[0294] ND P25-040-PCTU1

[0295]

[0296]

[0297] MTT Assay Results (50% Tox; HepG2):a> 25 pM,b> 50 |xM,c> 100 |xM,d> 200 pM.

[0298] 501.119WO1

[0299] ND P25-040-PCTExample 2, Pharmaceutical Dosage Forms.

[0300] The following formulations illustrate representative pharmaceutical dosage forms that may be used for the therapeutic or prophylactic administration of a compound of a formula described herein, a compound specifically disclosed herein, or a pharmaceutically acceptable salt or solvate thereof (hereinafter referred to as 'Compound X'):

[0301] Tablet 1 mg / tablet

[0302] 'Compound X' 100.0

[0303] Lactose 77.5

[0304] Povidone 15.0

[0305] Croscarmellose sodium 12.0

[0306] Microcrystalline cellulose 92.5

[0307] Magnesium stearate 3.0

[0308] 300.0

[0309] (ii) Tablet 2 mg / tablet

[0310] 'Compound X' 20.0

[0311] Microcrystalline cellulose 410.0

[0312] Starch 50.0

[0313] Sodium starch glycolate 15.0

[0314] Magnesium stearate 5.0

[0315] 500.0

[0316] (iii) Capsule mg / capsule

[0317] 'Compound X' 10.0

[0318] Colloidal silicon dioxide 1.5

[0319] Lactose 465.5

[0320] Pregelatinized starch 120.0

[0321] Magnesium stearate 3.0

[0322] 600.0

[0323] (iv) Injection 1 (1 mg / mL) mg / mL

[0324] 'Compound X' (free acid form) 1.0

[0325] Dibasic sodium phosphate 12.0

[0326] Monobasic sodium phosphate 0.7

[0327] Sodium chloride 4.5

[0328] 1.0 N Sodium hydroxide solution q.s.

[0329] (pH adjustment to 7.0-7.5)

[0330] Water for injection q.s. ad 1 mL

[0331] (v) Injection 2 (10 mg / mL) mg / mL

[0332] 'Compound X' (free acid form) 10.0

[0333] Monobasic sodium phosphate 0.3

[0334] Dibasic sodium phosphate 1.1

[0335] Polyethylene glycol 400 200.0

[0336] 0.1 N Sodium hydroxide solution q.s.

[0337] (pH adjustment to 7.0-7.5)Water for injection q.s. ad 1 mL

[0338] (vi) Aerosol mg / can 'Compound X' 20 Oleic acid 10 Trichloromonofluoromethane 5,000 Dichlorodifluoromethane 10,000 Dichlorotetrafluoroethane 5,000 (vii) Topical Gel 1 wt.% 'Compound X' 5% Carbomer 934 1,25% Triethanolamine q.s.

[0339] (pH adjustment to 5-7)

[0340] Methyl paraben 0.2% Purified water q.s. to 100g (viii) Topical Gel 2 wt.% 'Compound X' 5% Methylcellulose 2% Methyl paraben 0.2% Propyl paraben 0.02% Purified water q.s. to 100g (ix) Topical Ointment wt.% 'Compound X' 5% Propylene glycol 1% Anhydrous ointment base 40% Polysorbate 80 2% Methyl paraben 0.2% Purified water q.s. to 100g (x) Topical Cream 1 wt.% 'Compound X' 5% White bees wax 10% Liquid paraffin 30% Benzyl alcohol 5% Purified water q.s. to 100g (xi) Topical Cream 2 wt.% 'Compound X' 5% Stearic acid 10% Glyceryl monostearate 3% Polyoxyethylene stearyl ether 3% Sorbitol 5% Isopropyl palmitate 2 % Methyl Paraben 0.2% Purified water q.s. to 100gThese formulations may be prepared by conventional procedures well known in the pharmaceutical art. It will be appreciated that the above pharmaceutical compositions may be varied according to well-known pharmaceutical techniques to accommodate differing amounts and types of active ingredient 'Compound X'. Aerosol formulation (vi) may be used in conjunction with a standard, metered dose aerosol dispenser. Additionally, the specific ingredients and proportions are for illustrative purposes. Ingredients may be exchanged for suitable equivalents and proportions may be varied, according to the desired properties of the dosage form of interest.

[0341] All publications, patents, and patent documents cited herein are incorporated by reference as though individually incorporated by reference. No limitations inconsistent with this disclosure are to be understood therefrom. The invention has been described with reference to various specific and preferred embodiments and techniques. However, many variations and modifications may be made while remaining within the spirit and scope of the invention.

[0342] While specific embodiments have been described above with reference to the disclosed embodiments and examples, such embodiments are only illustrative and do not limit the scope of the invention. Changes and modifications can be made in accordance with ordinary skill in the art without departing from the invention in its broader aspects as defined in the following claims.

Claims

What is claimed is:

1. A compound of Formula I:Heteroaryl-Amido (I),wherein,Heteroaryl is represented by Formula LAI, IA2, IA3, or 1 A4:wherein,each J1is S, 0, or NRawherein Rais H or -(Ci-Ce)alkyl;each J2is CRbwherein Rbis H or -(Ci-Ce)alkyl, or each J2is N;each R1is H, halo, or -(Ci-Ce)alkyl;each Rlbis H, halo, or -(Ci-C6)alkyl; andeach R2is H, halo, or -(Ci-C6)alkyl;Amido is represented by Formula IB1:Amin (IB1),wherein,Amin is heterocycloalkyl or N(RC)2 wherein each Rcis independently -(Ci-C6)alkyl;L is absent or NRCwherein Rcis H or -(Ci-C6)alkyl;R3is H or -(Ci-Ce)alkyl;R4is H, halo, or unsubstituted or substituted -(Ci-Ce)alkyl; andR5is H, -(Ci-Ce)alkyl, or halo provided that halo is not ortho to the amide moiety of Formula 1B1;or salt thereof; andprovided that the compound is not 3-chloro-A-(3-chloro-4-(4-methylpiperazin-l-yl)phenyl)benzo[b]thiophene-2-carboxamide.

2. The compound of claim 1, wherein the Heteroaryl moiety of Formula I is represented by Formula IA1.

3. The compound of claim 2, wherein the Heteroaryl moiety represented by Formula IA1 is Formula IA5:wherein Rbis H, halo, or -(Ci-C6)alkyl.

4. The compound of claim of 3, wherein the Heteroaryl moiety represented by Formula IA5 is:

5. The compound of claim 1, wherein the Heteroaryl moiety of Formula I is represented by Formula IA2, wherein J1is S and J2is CH,6. The compound of claim 1, wherein the Amido moiety of Formula I is represented by Formula IB 2:Aminwherein R4is H, Cl, CF3, or CH3.

7. The compound of claim 6, wherein R3is halo or -(Ci-C6)alkyl and R5is positioned meta relative to R4.

8. The compound of claim 7, wherein Amin is a 5- or 6-membered nitrogenheterocycloalkyl.

9. The compound of claim 7, wherein Amin is piperidine, piperazine, morpholine, pyrrolidine, or dimethylamine.

10. The compound of claim 7, wherein Amin is positioned ortho relative to R4.

11. The compound of claim 7, wherein Amin is positioned meta relative to R4.

12. The compound of claim 7, wherein Amin is positioned para relative to R4.

13. The compound of any one of claims 1 or 6-9, wherein Amin is:

14. The compound of claim 1, wherein the compound is:

15. A method for treating a methicillin-resistant Staphylococcus aureus (MRS A) infection comprising administering to a subject in need thereof a combination of an antibiotic and an adjuvant comprising a compound of Formula I:Heteroaryl-Amido (I),wherein,Heteroaryl is represented by Formula LAI, IA2, IA3, or 1 A4:wherein,each J1is S, 0, or NRawherein Rais H or -(Ci-Ce)alkyl;each J2is CRbwherein Rbis H or -(Ci-Ce)alkyl, or each J2is N;each R1is H, halo, or -(Ci-Ce)alkyl;each Rlbis H, halo, or -(Ci-Ce) alkyl; andeach R2is H, halo, or — (Ci-Ce)alkyl;Amido is represented by Formula IB 1:Amin (IB1),wherein,Amin is heterocycloalkyl or N(RC)2 wherein each Rcis independently -(Ci-Ce)alkyl;L is absent or NRCwherein Rcis H or -(Ci-C6)alkyl;R3is H or -(Ci-Ce)alkyl;R4is H, halo, or unsubstituted or substituted -(Ci-Ce)alkyl; andR5is H, -(Ci-Ce)alkyl, or halo provided that halo is not ortho to the amide moiety of Formula 1B1;or a salt thereof: wherein the MRSA infection is thereby treated.

16. The method of claim 15, wherein the antibiotic is oxacillin.

17. The method of claim 15, wherein the MRSA infection is osteomyelitis.

18. The method of any one of claims 15-17, wherein the method mediates colonization of the cortical bone osteocyte lacuna-canalicular network (OLCN) in the subject.

19. The method of any one of claims 15-17, wherein the compound inhibits penicillin binding protein 4 (PBP4), penicillin binding protein 2a (PBP2a), or both.

20. The method of any one of claims 15-17, wherein the compound is: